OpenEvidence Raises $210M in Series B Funding
OpenEvidence, a company based in Cambridge, MA, that specializes in medical search and AI applications, has secured $210 million in Series B funding. The investment round was led by Sequoia Capital, Coatue, Conviction, and Thrive.
Expansion Plans and Strategic Partnerships
The funding will be used by OpenEvidence to expand its strategic content partnerships, aiming to enhance its library of advanced medical knowledge. The company, founded by Daniel Nadler and Zachary Ziegler, offers a clinical decision support platform that is widely used in over 10,000 hospitals and medical centers across the United States.
OpenEvidence has also announced key partnerships with prestigious medical institutions such as the American Medical Association (JAMA) and The New England Journal of Medicine. These collaborations will provide access to full-text content and multimedia from leading medical sources to inform the platform’s solutions.
Significant Investment and Growth
With this latest funding round, OpenEvidence has now raised over $300 million since its inception. The company’s platform is utilized by over 40% of physicians in the United States, who rely on it daily to make critical clinical decisions at the point of care.
Overall, OpenEvidence’s success in securing substantial funding and forming strategic partnerships underscores its position as a leading provider of innovative medical search and AI solutions in the healthcare industry.
